Introduction {#sec1-1}
============

Coronary artery disease (CAD) belongs to the cardiovascular disease (CVD) group, which includes the heart and blood vessels, resulting from the build-up of plaques in the coronary arteries and the ruptured plaques that may induce thrombosis in coronary atherosclerosis ([@ref1]). CAD is the leading cause of death including both morbidity and mortality globally, especially in developing countries ([@ref2], [@ref3]). Despite the genetic basis for CAD remains relatively unknown, previous studies suggested that several independent risk factors including smoking, hypercholesterolemia, hypertension, obesity, and diabetes have a strong association for the developing CAD pathology ([@ref4]). Recently, genome-wide association studies (GWAS) have reported the locus codes for an antisense RNA (*CDKN2B-AS1* or ANRIL), which is located nearby the *CDKN2A--CDKN2B* gene cluster with an increased susceptibility to CAD or myocardial infraction in carriers of the particular single-nucleotide polymorphisms (SNPs) within the chromosome 9p21.3 locus ([@ref5]--[@ref12]). Although these SNPs are located within the intronic region, their functional link still remains suppositional ([@ref13]). The risk alleles of the CAD-associated variants were shown to be strongly associated with an increased of CAD pathogenesis 20% to 30% ([@ref14]). The *CDKN2B-AS1* gene encodes a functional RNA molecule that interacts with polycomb repressive complex 1 (PRC1) and 2 (PRC2), suggesting epigenetic silencing of other genes in the *CDKN2A--CDKN2B* gene cluster ([@ref15]). SNPs within this region that influenced the *CDKN2B* expression are involved in the pathogenesis of atherosclerosis, whereas *CDKN2B* is a downstream target for transforming growth factor (TGF)-β that suggested its role in the TGF-β-induced growth inhibition ([@ref16], [@ref17]). Even though its molecular mechanism is still not clear, it is known that TGF-β plays an important role in maintaining normal vessel wall structure, and a lack of this function affects the development of atherosclerosis ([@ref18]). *MTAP* is a protein-coding gene that encodes the ubiquitously expressed enzyme methylthioadenosine phosphorylase close to the chr9p21.3 region ([@ref17]). *MTAP* belongs to the polyamine metabolism and plays an important role in releasing adenine and methionine ([@ref19]).

Common variants of *CDKN2B-AS1* (including rs4977574 A\>G/T and rs1333040 C\>T) are determined to be directly associated with CADs in many populations worldwide and suggested biomarkers for the early detection of CAD ([@ref20]--[@ref26]). However, there is a lack of investigation for the association between *CDKN2B-AS1* rs4977574 A\>G/T and rs1333040 C\>T genetic modifiers and CAD in a Turkish Cypriot population. Turkish Cypriots are a developing society and have a relatively high ratio of CVD, which could be due to lifestyle, unhealthy diet, and restrictive Island-spesific gene pool ([@ref27]). The aim of the present study was to investigate the potential effects of *CDKN2B-AS1* rs4977574 A\>G/T and rs1333040 C\>T polymorphisms on susceptibility to CAD in a Turkish Cypriot population.

Methods {#sec1-2}
=======

A total of 224 unrelated volunteers who belong to the Turkish Cypriot population were included in the study. The study protocol was approved by the Institutional Review Board (NEU/2016/36/382). Informed consent was obtained from all study participants. Each subject was provided with a questionnaire to determine personal characteristics, including age, ethnicity, and general health status. The Turkish Cypriot ethnicity was defined as residing in North Cyprus as well as being born to parents who have been living in the island of Cyprus for at least three generations. Additionally, considering the small size of the island population and high number of relatives in North Cyprus, subjects who are relatively related were excluded from the study. One hundred fifty-three healthy subjects with no clinical evidence of type 2 diabetes, hypertension, obesity, hypercholesterolemia, family/history of stroke, or transient ischemic attacks and 71 patients with angiography-confirmed CAD who were diagnosed by a cardiologist constituted two study groups (control group and CAD group, respectively). Antecubital venous blood from the subjects was collected in tubes containing Ethylenediaminetetraacetic acid (EDTA) and centrifuged within 2 h of collection. The fasting levels of plasma glucose, serum total cholesterol, high-density lipoprotein-cholesterol (HDL-C), low-density lipoprotein-cholesterol (LDL-C), and triglyceride (TG) were measured using an automatic biochemical analyzer \[Clinical Biochemistry Analyzer (CA); JEOL, Japan\] in the Medical Biochemistry Laboratory of the Near East University Hospital.

Genotyping {#sec2-1}
----------

DNA was extracted using PureLink Genomic DNA Mini Kit (Thermo Fisher Scientific, USA). Two *CDKN2B-AS1* (rs4977574 A\>G/T and rs1333040 C\>T) polymorphisms were analyzed by polymerase chain reaction (PCR) restriction fragment length polymorphism according to previous studies ([@ref28], [@ref29]). PCR was performed in a total reaction volume of 25 µl in 200 µl tubes on an Applied Biosystems Veriti Thermal Cycler. The reaction mixture consisted of 10 ng genomic DNA, 0.5 µM forward and reverse primers ([Table 1](#T1){ref-type="table"}), 1× Taq polymerase buffer with KCL (Thermo Scientific, EP0402), 1.5 mM MgCl2 (Thermo Scientific), 200 mM dNTP mix (Thermo Scientific, R0191), and 1.5 U Taq polymerase (Thermo Scientific, EP0402). A class II laminar flow hood, designated pipettes, PCR clean plasticware and reagents, and ultraviolet-treated solutions were used to minimize the risk of contamination during DNA extraction and PCR preparation. The digested fragments were separated in 2% agarose gels and visualized by ethidium bromide staining. Genotypes were determined according to the presence and absence of restriction sites, and alleles were designated with respect to actual base change according to the dbSNP (<https://www.ncbi.nlm.nih.gov/SNP/>) and Ensembl (<http://www.ensembl.org/>) websites ([Table 1](#T1){ref-type="table"}).

###### 

The details of PCR primers and restriction enzymes for the *CDKN2B-AS1* gene SNPs rs4977574 A\>G and rs1333040 C\>T.

  SNP                                      Primers                              Restriction enzyme   Reference
  ---------------------------------------- ------------------------------------ -------------------- -----------
  rs4977574                                F 5'-ATAGGGGTTATGGGAAATGC - 3'       *Hhal*               29
  R 5'- AAACCTAAAAGGGCTTGCTGA - 3'                                                                   
  rs1333040                                F 5' - TCTGGAAGCACTGGGAAGGATG - 3'   *Bsml*               30
  R 5'- TTG ATT TGG GAG CCA CTG TTG - 3'                                                             

SNP - single-nucleotide polymorphism

Statistical analysis {#sec2-2}
--------------------

Data were expressed as mean±standard deviation for normally distributed continuous variables. Intergroup differences in continuous variables were assessed by the Student's unpaired t-test. Genotype distributions and allele frequencies were calculated by the gene-counting method, and their compliance to the Hardy--Weinberg equilibrium (HWE) was evaluated by the Pearson's goodness-of-fit chi-square, log likelihood ratio chi-square, and Fisher's exact test. The association between the case--control status and each polymorphism was assessed by the odds ratio and its corresponding 95% confidence interval. The influence of the assigned genotypes on biochemical parameters was evaluated using a one-way analysis of variance (ANOVA) for each polymorphism. The aforementioned single-locus data analyses were performed using the commercial GraphPad Prism software (GraphPad Software Inc., San Diego, CA, USA). The HaploBlock software was used for haplotype and linkage disequilibrium analyses. A p value \<0.05 was considered statistically significant.

Results {#sec1-3}
=======

Demographic, clinical, and laboratory characteristics of the studied group {#sec2-3}
--------------------------------------------------------------------------

The personal characteristics and biochemical parameters of the subjects, from whom blood samples were obtained, are shown in [Table 2](#T2){ref-type="table"}. The subjects comprised 224 Turkish Cypriot individuals, including 71 patients with CAD and 153 Turkish Cypriots as the control group. The CAD group showed no statistically significant difference from the control group with respect to age, fasting plasma glucose levels, and serum concentrations of total cholesterol, HDL-C, and LDL-C, whereas the serum concentrations of TG were significantly higher in the CAD group than in the control group (p=0.001). It should be noted, however, that the serum concentrations of TG in the CAD group (153.2±66.0 mg dL−1) are within the slightly higher than normal range of \>150 mg dL−1 (National Cholesterol Education Program Expert Panel, 2002), which should not be a major risk factor for heart disease nor considered protective against heart disease.

###### 

Basic characteristics of all studied subjects

  Variable                 Control n=153   Two-tailed n=71   *P* value
  ------------------------ --------------- ----------------- -----------
  Age (years)              41.4±11.5       44.9±15.0         0.092
  Sex                      64.7% F         63.4% F           
  35.3% M                  36.6% M         0.847             
  Glucose (mg dL-1)        92.5±24.2       96.1 ±24.2        0.421
  Cholesterol (mg dL-1)    196.3±51.9      202.8±42.6        0.432
  54.6±13.1                50.9±10.9       0.092             
  129.4±41.2               130.1 ±30.9     0.920             
  Triglyceride (mg dL-1)   113.1±43.0      153.2±66.0        0.001

Data are represented as mean±standard deviation.

M - male, F - female

Patients with abnormal lipid levels were identified by cut-off points of \>90 mg dL-1 for glucose, \>200 mg dL-1 for total cholesterol, \>130 mg dL-1 for LDL-cholesterol, \>40 mg dL-1 for HDL-cholesterol, and \>150 mg dL-1 for triglycerides

Distribution of the *CDKN2B-AS1* gene polymorphisms in the studied population {#sec2-4}
-----------------------------------------------------------------------------

The genotype distributions and allele frequencies of *CDKN2B-AS1* rs4977574 A\>G and rs1333040 C\>T among the 71 cases and 153 controls are shown in [Table 3](#T3){ref-type="table"}. The distributions of the *CDKN2B-AS1* rs4977574 A\>G and rs1333040 genotypes were in compliance with the HWE (p\>0.050). The frequencies of the minor alleles *CDKN2B-AS1* rs4977574 G and rs1333040 C among the case group were 0.43 and 0.25, respectively. The minor allele frequency for *CDKN2B-AS1* rs1333040 C in the control group was similar with the case group (0.26), whereas *CDKN2B-AS1* rs4977574 had equal allele frequency for both G and T alleles (0.50/0.50). To test the genetic association using the case--control study design, data for a single biallelic marker calculation were adapted from Sasieni ([@ref30]). The comparison test for association and for deviation from the HWE did not present any statistical difference between the two studied groups and analyzed SNP genotypes ([Table 4](#T4){ref-type="table"}).

###### 

Genotype and allele frequencies for the two *CDKN2B-AS1* gene polymorphisms, rs4977574 A\>G/T and rs1333040 C\>T, in the two groups

                   Genotype/allele   CAD n^[a](#t3f1){ref-type="table-fn"}^ (%)   Control n^[b](#t3f2){ref-type="table-fn"}^ (%)   OR            95% CI   *P*^[\*](#t3f3){ref-type="table-fn"}^
  ---------------- ----------------- -------------------------------------------- ------------------------------------------------ ------------- -------- ---------------------------------------
  rs4977574        AA                24 (33.9)                                    39 (23.5)                                                               
  AG               33 (46.4)         76 (49.6)                                                                                                            
  GG               14 (19.7)         38 (24.9)                                                                                                            
  A                81 (57.0)         154 (50.3)                                                                                                           
  G                61 (43.0)         152 (49.7)                                   1.310                                            0.877-1.956   0.185    
  HWE *P*- value                     0.935                                        0.663                                                                   
  rs1333040        CC                4 (5.6)                                      14 (9.2)                                                                
  CT               28 (39.4)         53 (34.6)                                                                                                            
  TT               39 (55.0)         86 (56.2)                                                                                                            
  C                36 (25.3)         81 (26.5)                                                                                                            
  T                106 (74.7)        225 (73.5)                                   1.06                                             0.672-1.671   0.06     
  HWE *P*-value                      0.173                                        0.723                                                                   

n=71

n=153

Pearson chi-square test.

Hardy-Weinberg equilibrium test was performed to compare the observed and expected genotypes and to compute the allele frequencies as well as *P* values for each single- nucleotide polymorphism.

HWE - Hardy-Weinberg equilibrium; CI - confidence interval

###### 

The tests for association and for deviation from the HWE are adapted from Sasieni ([@ref31])

  SNPs        Tests for deviation from HWE   Tests for association (95% CI)                                                                                       
  ----------- ------------------------------ -------------------------------- ----------------- ------------------- ---------------------- ---------------------- -----------------
                                                                              Risk allele G                                                                       
                                                                              \[A\]\<-\>\[G\]   \[A\]\<-\>\[G\]     \[A\]\<-\>\[G\]        \[A\]\<-\>\[G\]        \[A\]\<-\>\[G\]
                                                                              OR=0.763          OR=0.763            OR=0.763               OR=0.763               OR=0.763
              AA=39                          AA=24                            CI=0.511-1.139    CI=0.511-1.139      CI =0.511-1.139        CI=0.511-1.139         CI =0.511-1.139
              AG=76                          AG=33                            X^2^=1.75         X^2^=1.75           X^2^=1.75              X^2^=1.75              X^2^=1.75
              GG=38                          GG=14                            *P*=0.185         *P*=0.185           *P*=0.185              *P*=0.185              *P*=0.185
  rs4977574   f_a1=0.50 ±0.029               f_a1=0.57 ±0.043                 Risk allele A                                                                       
              F=0.006                        F=0.051                          \[G\]\<-\>\[A\]   \[GG\]\<-\>\[AG\]   \[AG+GG\]\<-\>\[AA\]   \[AA+AG\]\<-\>GG\]     Common OD's
              *P*=0.935                      *P*=0.663                        OR=1.311          OR=1.179            OR=1.670               OR=1.345               OR=1.297
                                             CI=0.878-1.957                   CI=0.564-2.462    CI=0.753-3.704      CI=0.675-2.683         X^2^=1.71              
                                                                              X^2^=1.75         X^2^=0.19           X^2^=1.61              X^2^=0.71              *P*=0.190
                                                                              *P*=0.185         *P*=0.661           *P*=0.204              *P*=0.398              
                                                                              Risk allele T                                                                       
                                                                              \[C\]\<-\>\[T\]   \[CC\]\<-\>\[CT\]   \[CC+CT\]\<-\>\[TT\]   \[CC\]\<-\>\[CT+TT\]   Common OD's
                                                                              OR=1.060          OR=1.849            OR=1.587               OR=1.687               OR=1.128
              CC=14                          CC=4                             CI=0.672-1.672    CI=0.556-6.150      CI=0.491-5.134         CI=0.535-5.322         X^2^=0.06
              CT=53                          CT=28                            X^2^=0.06         X^2^=1.03           X^2^=0.60              X^2^=0.81              *P*=0.807
              TT=86                          TT=39                            *P*=0.802         *P*=0.311           *P*=0.437              *P*=0.367              
  rs1333040   f_a1=0.26 +/-0.027             f_a1=0.25 +/-0.036               Risk allele C                                                                       
              F=0.110                        F=-0.041                         \[T\]\<-\>\[C\]   \[TT\]\<-\>\[CT\]   \[TT\]\<-\>\[CC\]      \[CC+CT\]\<-\>\[TT\]   Common OD's
              *P*=0.173                      *P*=0.723                        OR=0.943          OR=1.165            OR=0.630               OR=1.053               OR=0.898
              \-                                                              CI=0.598-1.488    CI=0.643-2.110      CI=0.195-2.038         CI=0.598-1.855         X^2^=0.06
                                                                              X^2^=0.06         X^2^=0.25           X^2^=0.60              X^2^=0.03              *P*=0.807
                                                                              *P*=0.802         *P*=0.614           *P*=0.437              *P*=0.857              

The evaluation of genotype comparison did not show any statistical significance between the CAD and control groups. f\_ al: frequency of allele 1±standard deviation, F: inbreeding coefficient.

HWE - Hardy-Weinberg equilibrium; CI - confidence interval; OR - odd ratio; SNP - single-nucleotide polymorphism

Comparison of the two *CDKN2B-AS1* rs4977574 A\>G/T and rs1333040 C\>T gene polymorphisms with clinical parameters within the case--control subjects {#sec2-5}
----------------------------------------------------------------------------------------------------------------------------------------------------

The distribution of all biochemical parameters according to the *CDKN2B-AS1* genotypes in the case--control populations is presented in [Table 5](#T5){ref-type="table"}. ANOVA standard weighted-means analysis for independent samples (df: 2) was made to determine the association studies for the other two APOA5 SNPs and biochemical parameters. No association between the two studied *CDKN2B-AS1* polymorphisms (rs4977574 and rs1333040) and the biochemical components of glucose, serum LDL-C, and TG was observed in both the case and control groups. On the other hand, a strong statistically significant association between serum total cholesterol clinical parameter and *CDKN2B-AS1* rs4977574 GG and rs1333040 TT genotypes was found (p=0.019 and p=0.022, respectively) in the CAD group. Moreover, the same strong statistical significant association has been observed between HDL-C and *CDKN2B-AS1* rs4977574 GG and rs1333040 TT genotypes (p=0.006 and p=0.031, respectively). Individuals who are homozygous for either *CDKN2B-AS1* rs4977574 GG or rs1333040 TT genotype have an increased number of serum total cholesterol and decrease HDL-C levels (240.8±70.2 and 246.3±71.4 for total cholesterol and 44.0±08.4 and 46.1±13.7 for HDL-C, respectively).

###### 

Comparison of the *CDKN2B-AS1* gene rs4977574 A\>G and rs1333040 C\>T polymorphisms with clinical parameters within both studied groups

  Clinical parameters                    rs4977574 A\>G                    ANOVA *P* value
  ------------------------- ------------ -------------------- ------------ ---------------------
  Glucose (mg dL-1)         90.6±09.0    94.6±33.3            90.3±7.9     0.720
  Cholestrol (mg dL-1)      197.2±49.8   196.1±60.6           195.8±38.4   1.000
  HDL-C (mg dL-1)           55.5±13.1    55.2±14.5            52.9±10.9    0.746
  LDL-C (mg dL-1)           122.7±39.9   135.0±44.4           124.7±36.7   0.480
  Triglyceride (mg dL-1)    123.6±46.4   115.6±39.5           101.0±45.5   0.236
  **Clinical parameters**                                                  **ANOVA *P* value**
  **CAD**                   **GG**       **AG**               **AA**       
  Glucose (mg dL-1)         100.5±18.0   101.6±21.1           95.5±10.5    0.756
  Cholestrol (mg dL-1)      240.8±70.2   202.1±43.7           213.0±40.9   0.019
  HDL-C (mg dL-1)           44.0±08.4    53.1±09.9            56.0±12.9    0.006
  LDL-C (mg dL-1)           130.2±43.8   128.5±31.8           102.1±20.3   0.109
  Triglyceride (mg dL-1)    188.2±44.9   103.6±40.3           90.5±19.2    0.305
  **Clinical parameters**                **rs1333040 C\>T**                **ANOVA *P* value**
  **Control**               **CC**       **CT**               **TT**       
  Glucose (mg dL-1)         91.2±10.8    89.9±10.2            95.3±32.3    0.608
  Cholestrol (mg dL-1)      195.9±57.6   197.1±44.6           203.4±53.2   0.951
  HDL-C (mg dL-1)           51.4±07.5    52.2±11.5            44.9±27.9    0.361
  LDL-C (mg dL-1)           135.8±53.4   127.0±37.9           131.1±43.1   0.869
  Triglyceride (mg dL-1)    109.0±37.5   111.6±47.6           115.6±41.3   0.904
  **Clinical parameters**                                                  **ANOVA *P* value**
  **CAD**                   **CC**       **CT**               **TT**       
  Glucose (mg dL-1)         95.4±11.5    101.9±21.1           101.1±19.1   0.795
  Cholestrol (mg dL-1)      199.9±47.0   201.1±38.1           246.3±71.4   0.022
  HDL-C (mg dL-1)           55.9±11.7    47.7±4.5             46.1±13.7    0.031
  LDL-C (mg dL-1)           108.7±11.9   126.4±31.6           140.6±23.8   0.762
  Triglycerid (mg dL-1)     104.0±29.5   113.8±77.2           183.6±96.9   0.028

CAD - coronary artery disease; HDL-C - high-density lipoprotein-cholesterol; LDL-C - low-density lipoprotein-cholesterol

Haplotype analysis {#sec2-6}
------------------

Linkage equilibrium analysis was made to determine and better understand the -cis regulation effect of both rs4977574 and rs1333040 intronic variants in patients with CAD. All observed haplotypes have been compared with each other The comparison analysis of -cis configuration analysis showed no observed difference between both *CDKN2B-AS1* SNP (rs4977574 and rs1333040) genotypes in a Turkish Cypriot population with CAD (data not shown).

Discussion {#sec1-4}
==========

For the last decade, GWAS mostly examined the molecular factors involved in the pathological development of CAD ([@ref31]). GWAS meta-analysis investigations revealed that the chr9p21.3 region contains several SNPs that are directly associated with CAD risk, especially with a younger age of onset ([@ref32]). Previously, two *CDKN2B-AS1* gene variants (rs4977574 A\>G and rs1333040 C\>T) within the chr9p21.3 locus were found to be associated with CAD risk ([@ref20], [@ref32]).

Thus, in the present study, we attempted to investigate the association of the *CDKN2B-AS1* rs4977574 A\>G and rs1333040 C\>T polymorphisms with the risk of CAD in an islandic population of White Caucasian of Turkish Cypriot origin. To our knowledge, this is the first study in the relevant scientific literature to examine the *CDKN2B-AS1* gene polymorphisms in this population and better understand the genetic predisposition of Turkish Cypriots to CAD, in addition to the expected Mediterranean diet.

Several GWAS and replication studies have shown a consistent association with the non-protein-coding SNP rs4977574 A\>G and the risk of CAD in populations of European or Eastern Asian descent ([@ref33]--[@ref36]). GWAS also showed that individuals with the rs4977574 AA genotype have higher risk of coronary heart diseases after controlling for potential confounders including age, sex, body mass index, cigarette smoking, hypertension, diabetes, and hyperlipidemia ([@ref37]). Recently, Lu et al. ([@ref38]) found that the rs4977574 G allele is potentially associated with non-cardioembolic cerebral infarction and carotid plaque in a Chinese Han population. Controversially, Cheng et al. ([@ref39]) presented that there is no association between the rs4977574 variant and stroke subtypes. Moreover, Hindy et al. ([@ref40]) suggested that rs4977574 interacts with vegetable and wine intake--main sources of Mediterranean diet--to affect the incidence of CAD. Previously, an independent SNP in the *CDKN2A/B* locus near the 9p21 53-kb LD block has been robustly associated with type 2 diabetes due to the rs4977574 risk allele associated with elevated glycated hemoglobin levels among individuals with a lower vegetable intake ([@ref40]-[@ref42]). In the same study, they observed manipulations of the association between rs4977574 and HDL-C levels by smoking, providing evidence that pathological risk may increase with environmental factors, leading to derangements at the level of glucose and lipid metabolism ([@ref40]). In the present study, there is no statistically significant association observed between rs4977574 SNP and two studied groups (p=0.185). However, the rs4977574 G allele was found to be associated with higher level of serum total cholesterol and lower level of HDL-C in the CAD group (p=0.019 and p=0.006, respectively).

Various studies previously have indicated that the rs1333040 C\<T polymorphism was significantly associated with the risk of development of CAD in North Indian ([@ref43]), German ([@ref31]), and Chinese Taiwanese ([@ref44]) populations, but not in Iranian ([@ref45]) and Chinese Han ([@ref37]). Beckie et al. ([@ref46]) have suggested that the risk allele for rs1333040 among Black women is diagnosed for coronary heat diseases 6.5 years earlier compared with those with the good allele, whereas this effect was absent in White women. In the present study, there is no association shown between rs1333040 SNP and two studied groups (p=0.802). On the other hand, the rs1333040 T allele--risk variant--was found to be associated with higher level of serum total cholesterol and lower level of HDL-C in the Turkish Cypriot CAD group (p=0.022 and p=0.031, respectively). HDL-C is believed to reflect the ability of HDL particles to remove excess cholesterol molecules from peripheral cells for return to the liver ([@ref46], [@ref47]). Therefore, lower level of HDL-C will not be able to protect cholesterol hierarchy as increase levels result in atherosclerotic plaques that cause CADs. To our knowledge, this is the first study that establishes the effect of rs1333040 on lipid metabolism.

Study limitations {#sec2-7}
-----------------

As with many other genetic association studies, the present study also has several limitations. First, the number of subjects included in our study is relatively small, and this lowers the statistical power. Second, the rs4977574 A\>G and rs1333040 C\>T polymorphisms are located within the intronic regions of the *CDKN2A/B* gene of chr9p21.3, and this confronts us with the challenge of precisely describing their functional relevance. Third, the epistatic interactions between the *CDKN2A/B* polymorphism and other genes and also *CDKN2A/B*--environment interactions remain to be thoroughly characterized, and this makes it difficult to draw definite conclusions about the causal connections between the *CDKN2A/B* variants and risk of CAD.

Conclusion {#sec1-5}
==========

In conclusion, the results from our study suggest the homozygous wild-type genotypes of rs4977574 GG and rs1333040 TT at the *CDKN2A/B* as a genetic risk factor with elevated serum total cholesterol and lower HDL-C effects in a Turkish Cypriot population with CAD. However, allele A for rs4977574 was found to be statistically higher in the CAD groups (p=0.014). With interaction with dominant lifestyles, minimal physical activity, and meat heavy fast food culture in the population, these risk alleles may affect lipid metabolism. Thus, these SNPs could have clinical importance as predisposition biomarkers. The relatively small number of inhabitants in North Cyprus calls for GWAS of CAD and other CVDs in a Turkish Cypriot population. Further study is required to determine the functional effects of these SNPs and validate these findings in larger populations.
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